Gonadorelin results: what to expect and when
A short-acting fertility hormone used in tests and specialist pump therapy.
Also called: GnRH, LHRH, gonadorelin acetate, gonadorelin hydrochloride, Factrel, Lutrepulse.
Reproductive axis peptides · Gonadotropin-releasing hormone receptor agonist · Evidence: Approved drug.
At least 51 studies in separate reviews, 35 in women and 16 in men. More reports are listed; twice-weekly shots alongside testosterone therapy lack a controlled fertility trial.
Key studies
- Hypothalamic amenorrhea: 35 studies: Pulsatile GnRH can induce ovulation in hypothalamic amenorrhea. (source)
- Male fertility: 16 GnRH studies: Pulsatile GnRH can restore sperm production in diagnosed hormone deficiency. (source)
- GnRH versus gonadotropins: Earlier sperm appearance did not establish a higher pregnancy rate. (source)
- Lutrepulse: multicenter fertility study: The historical program studied pump therapy, not occasional TRT injections. (source)
- LutrePulse: posted phase 3 results: Posted randomized results show an ovulation signal with higher pump doses. (source)
- FHA: 25-year pump cohort: Pump therapy produced high ovulation rates with few multiple pregnancies. (source)
Related to Gonadorelin
- Kisspeptin-10: A short-acting experimental peptide that triggers reproductive hormone release.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
Sources
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- FDA warning letter 729447: unapproved gonadorelin (2026-06-17), FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- FDA CDER alert: compounded-drug recall for lack of sterility assurance (2022-04-26), FDA · 2022
- Gonadorelin 100 micrograms powder for solution for injection, Esteve Pharmaceuticals · 2022
- Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment., Boehm U et al. · Nature reviews. Endocrinology · 2015
- Base de Données Publique des Médicaments, ANSM
- Drugs@FDA: FDA-Approved Drugs, FDA
- Drugs@FDA: FDA-Approved Drugs, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
- PREGNYL- choriogonadotropin alfa kit, Organon
- Product information, Health Canada
- Successful ovulation and pregnancy with pulsatile GnRH pump therapy in a polycystic ovary syndrome (PCOS) patient: a case report., Wang S et al. · Frontiers in endocrinology · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.